Skip to main content

Table 2 Progression-free survival (PFS) and overall survival (OS)

From: Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma

Variable

PFS/OS (M / %)

95%CI

Median PFS (M)

11.0

7.0–13.0

 At 1 year (%)

40.4

27.5–54.9

 At 2 year (%)

22.8

12.9–37.1

 At 3 year (%)

15.9

7.9–29.7

 At 4 year (%)

13.6

6.4–27.1

 At 5 year (%)

11.4

4.9–24.5

Median OS (M)

18.0

15.0–26.0

 At 1 year (%)

80.8

67.1–89.7

 At 2 year (%)

40.7

27.5–55.4

 At 3 year (%)

27.1

16.1–41.9

 At 4 year (%)

22.6

12.6–37.1

 At 5 year (%)

20.3

10.9–34.6

  1. CI Confidence interval